Why the study?
Fentanyl is a major contributor to fatal overdoses via opioid-induced respiratory depression (OIRD), but reversing overdoses is challenging due to high potency and rapid onset, prompting investigation into central versus peripheral MOR contributions.
Does naloxone methiodide reverse fentanyl-induced cardiorespiratory depression without causing aversive behavior in rats?
Does naloxone methiodide reverse fentanyl-induced cardiorespiratory depression without causing aversive behavior in rats?
Peripheral mu-opioid receptor antagonism effectively reverses fentanyl-induced respiratory depression without triggering centrally-mediated aversive withdrawal symptoms.
Hypothesis-generating for peripheral mu-antagonism in fentanyl reversal; human trials needed before clinical consideration.
Millions of Americans suffering from Opioid Use Disorders (OUD) face a high risk of fatal overdose due to opioid-induced respiratory depression (OIRD). Fentanyl, a powerful synthetic opioid, is a major contributor to the rising rates of overdose deaths. Reversing fentanyl overdoses has proved challenging due to its high potency and the rapid onset of OIRD. We assessed the contributions of central and peripheral mu opioid receptors (MORs) in mediating fentanyl-induced physiological responses. The peripherally restricted MOR antagonist naloxone methiodide (NLXM) both prevented and reversed OIRD to a degree comparable to that of naloxone (NLX), indicating substantial involvement of peripheral MORs to OIRD. Interestingly, NLXM-mediated OIRD reversal did not produce aversive behaviors observed after NLX. We show that neurons in the nucleus of the solitary tract (nTS), the first central synapse of peripheral afferents, exhibit a biphasic activity profile following fentanyl exposure. NLXM pretreatment attenuates this activity, suggesting that these responses are mediated by peripheral MORs. Together, these findings establish a critical role for peripheral MORs, including ascending inputs to the nTS, as sites of dysfunction during OIRD. Furthermore, selective peripheral MOR antagonism could be a promising therapeutic strategy for managing OIRD by sparing CNS-driven acute opioid-associated withdrawal and aversion observed after NLX.
No takes yet. Share an insight, caveat, or question.
Ruyle et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: